Review of drug interactions with telaprevir and antiretrovirals.

Abstract

HCV infection is a major cause of mortality worldwide. HCV-related deaths also represent a leading cause of mortality in HIV-coinfected individuals. Telaprevir is an NS3/4A protease inhibitor approved for the treatment of chronic HCV genotype 1 infection in adults in combination with pegylated interferon and ribavirin. Telaprevir-based treatment has been shown to increase rates of sustained viral response in HCV genotype-1-monoinfected patients, and studies in HCV-HIV-coinfected patients are ongoing. Drug-drug interactions of telaprevir with antiretroviral drugs were investigated in a series of studies in healthy subjects. This review summarizes the results of interaction studies with low-dose ritonavir, ritonavir-boosted HIV protease inhibitors (atazanavir, darunavir, fosamprenavir and lopinavir), efavirenz, etravirine, rilpivirine, tenofovir disoproxil fumarate and raltegravir.

• Authors: Rolf P G van Heeswijk, Maria Beumont, Robert S Kauffman, Varun Garg
• Journal: Antiviral therapy (Antivir Ther) Vol. 18 Issue 4 Pg. 553-60 ( 2013) ISSN: 2040-2058 [Electronic] England
• PMID: 23344266 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antiviral Agents
• Oligopeptides
• Protease Inhibitors
• Reverse Transcriptase Inhibitors
• telaprevir
• Ritonavir

Topics

• Adult
• Antiviral Agents (therapeutic use)
• Coinfection
• Drug Interactions
• Drug Therapy, Combination
• HIV Infections (drug therapy, virology)
• Hepacivirus (drug effects)
• Hepatitis C, Chronic (drug therapy, virology)
• Humans
• Male
• Oligopeptides (therapeutic use)
• Protease Inhibitors (therapeutic use)
• Reverse Transcriptase Inhibitors (therapeutic use)
• Ritonavir (therapeutic use)